Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer

Author(s): Qing Zhang, Huizhong Li, Jie Yang, Liantao Li, Baofu Zhang, Jia Li, Junnian Zheng

Journal Name: Current Gene Therapy

Volume 13 , Issue 1 , 2013

Become EABM
Become Reviewer
Call for Editor


Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. However, in solid tumors, the clinical responses have been less impressive. It is important to determine how to further improve the clinical effects of CAR-modified T cells. In this review, we focus on recent clinical trials and analyze the factors that determine clinical responses, including the following: 1) the composition of the CAR; 2) the preparation of CAR-modified T Cells; 3) the clinical treatment schedule; 4) the patient characteristics. We also propose future Strategies that must be investigated before the technology can be used in a wider range of clinical applications.

Keywords: Adoptive cell therapy, chimeric antigen receptor, T cell, cancer immunotherapy, cancer gene therapy, clinical trial, T cell receptor, single chain fragment variable

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 26 December, 2012
Page: [65 - 70]
Pages: 6
DOI: 10.2174/1566523211313010007

Article Metrics

PDF: 87